Company: NDRA
Filing Date: 2025-11-26
Form Type: 424B4
Source: 0001213900-25-115097
Chunk: 38

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-26
Form: 424B4
Chunk 38
---
 complied with.

Under applicable rules and
regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in
market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to
the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange
Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common
stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders
and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including
by compliance with Rule 172 under the Securities Act).

<div align='center'>20

LEGAL MATTERS</div>

The validity of the shares
of common stock offered hereby will be passed upon by K&L Gates LLP, Charlotte, North Carolina.

<div align='center'>EXPERTS</div>

RBSM LLP, independent registered
public accounting firm, has audited our financial statements included in our Annual Report on Form 10-K for the year ended December 31,
2024, which is incorporated by reference into this prospectus and elsewhere in the registration statement of which this prospectus is
a part. Our financial statements are incorporated by reference in reliance on RBSM LLP’s report, given on their authority as experts
in accounting and auditing.

<div align='center'>WHERE YOU CAN FIND MORE INFORMATION</div>

We file annual, quarterly
and current reports, proxy statements and other information with the SEC. The SEC maintains a web site that contains reports, proxy and
information statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website
is http://www.sec.gov.

The Company’s website
address is www.endrainc.com. Information on the Company’s website, any subsection, page, or other subdivision of the Company’s
website, or any website linked to by content on the Company’s website, is not part of this prospectus and you should not rely on
that information unless that information is also in this prospectus or incorporated by reference in this prospectus.

This prospectus and any prospectus
supplement are part of a registration statement on Form S-3 under the Securities Act we filed with the SEC and do not contain all of